Company Overview
Snapshot
Founded in April 2010 by Nini Bluman and Haim Hoffman, BioXtreme operates with 11–50 employees. The company has raised $5.67 million across 4 funding rounds from 5 investors. In March 2024, BioXtreme secured a grant from the Israel Innovation Authority.
Business overview
BioXtreme develops robotic systems for patient rehabilitation from strokes, traumatic brain injuries, and other neurological disorders. Its core products, DeXtreme and plaXtreme, integrate biofeedback and 3D virtual reality to precisely measure muscle strength and range of motion, aiming to reduce rehabilitation treatment times by 50%. The company operates within the Health Tech & Life Sciences sector, specifically focusing on medical devices and treatments for healthcare providers.
Strategic signal
In June 2022, BioXtreme's deXtreme™ robotic system was highlighted for its ability to shorten upper post-stroke limb rehabilitation by up to 50% using motor error enhancement forces in a virtual environment. This signals a significant advancement in rehabilitation technology, demonstrating potential for improved patient outcomes and efficiency in the healthcare industry, and indicating strong commercial viability as the company engages with global hospitals and distributors.
Log in to access full profile ›Company Intelligence Q&A
- What is BioXtreme's primary focus?
- BioXtreme specializes in developing robotics systems to assist in patient rehabilitation from strokes, traumatic brain injuries, and other neurological disorders.
- What is the DeXtreme system?
- DeXtreme is a robotic system developed by BioXtreme that integrates biofeedback and 3D virtual reality into real-life environments to assist in upper post-stroke limb rehabilitation.
- What is the purpose of plaXtreme?
- plaXtreme is an advanced robotic device designed to restore palm and finger motor skills in individuals who have experienced stroke, traumatic brain injuries, and other neurological conditions.